| Title |
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
|
|---|---|
| Published in |
Gastric Cancer, September 2014
|
| DOI | 10.1007/s10120-014-0420-9 |
| Pubmed ID | |
| Authors |
Taroh Satoh, Kyung Hee Lee, Sun Young Rha, Yasutsuna Sasaki, Se Hoon Park, Yoshito Komatsu, Hirofumi Yasui, Tae-You Kim, Kensei Yamaguchi, Nozomu Fuse, Yasuhide Yamada, Takashi Ura, Si-Young Kim, Masaki Munakata, Soh Saitoh, Kazuto Nishio, Satoshi Morita, Eriko Yamamoto, Qingwei Zhang, Jung-mi Kim, Yeul Hong Kim, Yuh Sakata |
Mendeley readers
The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 2% |
| Unknown | 90 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 22% |
| Researcher | 14 | 15% |
| Student > Doctoral Student | 9 | 10% |
| Student > Ph. D. Student | 8 | 9% |
| Other | 7 | 8% |
| Other | 18 | 20% |
| Unknown | 16 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 55% |
| Biochemistry, Genetics and Molecular Biology | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Nursing and Health Professions | 2 | 2% |
| Engineering | 2 | 2% |
| Other | 7 | 8% |
| Unknown | 19 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2018.
All research outputs
#7,755,290
of 23,577,761 outputs
Outputs from Gastric Cancer
#150
of 609 outputs
Outputs of similar age
#78,069
of 240,019 outputs
Outputs of similar age from Gastric Cancer
#3
of 7 outputs
Altmetric has tracked 23,577,761 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 609 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,019 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.